Holen Sie sich die Stockscreener-App
25.90
0.19%
-0.05
Vorhandelsmarkt:
25.94
0.04
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.95
Offen:
$26
24-Stunden-Volumen:
22.28M
Relative Volume:
0.60
Marktkapitalisierung:
$147.62B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
19.86
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
+2.25%
1M Leistung:
-3.36%
6M Leistung:
+3.43%
1J Leistung:
+12.41%
1-Tages-Spanne:
$25.76
$26.15
1-Wochen-Bereich:
$25.19
$26.15
52-Wochen-Spanne:
$22.88
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.90 | 147.90B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) Valuation Check After New HYMPAVZI Approval Vaccine Data And Oncology Collaboration - simplywall.st
[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
How The Investment Narrative For Pfizer (PFE) Is Shifting On Pipeline Hopes And Revenue Risks - Yahoo Finance
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - Yahoo Finance
Pfizer Inc. stock (US7170811035): Cancer focus and pipeline updates keep investors watching PFE - AD HOC NEWS
Pfizer's CEO uses AI to make his biggest calls — and 64% of CEOs agree, quietly shifting your portfolio - Yahoo Finance
Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38% - The Globe and Mail
Pfizer, Inc. (PFE) Stock Analysis: Exploring a 12.69% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Pfizer stock (US7170811035): oncology collaboration and cautious recovery draw fresh attention - AD HOC NEWS
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call Transcript - GuruFocus
Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns - Yahoo Finance UK
Pfizer Collaboration Targets Faster Cancer Trials While Shares Trade Below Value - simplywall.st
Pfizer’s SWOT analysis: stock navigates patent cliff with new drugs By Investing.com - Investing.com UK
The Most Important Healthcare Stock You're Not Watching - Yahoo Finance
PFE Stock Quote Price and Forecast - CNN
Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study - TipRanks
Pfizer class action alleges website tracked users despite cookie opt-outs - Class Action Lawsuits
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned? - Yahoo Finance Singapore
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
TREM2 agonists detailed in Pfizer patent - BioWorld News
Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks - Yahoo Finance
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A EffortsReiterate Buy (NYSE:PFE) - Seeking Alpha
Kimberly-Clark (KMB) vs Pfizer (PFE): Defensive Dividend Showdown for 2026 - Gotrade
Pfizer wins Singapore trademark dispute with Merck over vaccine brand - The Straits Times
PFE.DE Technical Analysis | Trend, Signals & Chart Patterns | PFIZER INC (FRA:PFE) - ChartMill
Pfizer Inc. stock (US7170811035): vaccine data and hemophilia approval put pharma giant back in focu - AD HOC NEWS
Pfizer Inc. Trade Ideas — BX:PFEUSD - TradingView
Goldman Sachs Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $26 - Moomoo
Building an AI-Fluent Organization: How Pfizer is helping colleagues understand, embrace, and apply AI - Pfizer
Building an AI-Literate Organization: How Pfizer is helping colleagues understand, embrace, and apply AI - Pfizer
Pfizer (PFE) Valuation Check After HYMPAVZI Expansion And Positive Pneumococcal Vaccine Data - Yahoo Finance
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and PfizerGlobal Forecast to 2030 and 2035 - Yahoo Finance Singapore
Comirnaty vaccine guide: how Pfizer's mRNA shot works - AD HOC NEWS
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer (PFE)? - simplywall.st
Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE) - Yahoo Finance
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Pfizer stock (US7170811035): new pediatric vaccine data and structured note spotlight long-term bets - AD HOC NEWS
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer - BioSpace
EBITDA of Pfizer Inc. – BVL:PFEUS - TradingView
Equity in earnings of Pfizer Inc. – BVL:PFEUS - TradingView
Pfizer Inc. Revenue Breakdown – BVL:PFEUS - TradingView
Pfizer Inc. Financial Statements – BVL:PFEUS - TradingView
Pfizer Inc. Income Statement – BVL:PFEUS - TradingView
ETFs Investing in Pfizer Inc. Stocks - TradingView
Free float of Pfizer Inc. – BVL:PFEUS - TradingView
Pfizer Moves Next-Gen Vaccine Into Phase III In Prevnar Lifecycle Strategy - Citeline News & Insights
Pfizer Options Spot-On: On May 20th, 91,964 Contracts Were Traded, With 2.54 Million Open Interest - Moomoo
Sarah Cannon Research Institute inks partnership with Pfizer - Nashville Post
Pfizer Inc (PFE) Stock Price, Trades & News - GuruFocus
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.96%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):